Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Acupuncture for Sleep Fragmentation in Older Adults: A Single-Arm Pilot Study

20 septembre 2026 mis à jour par: Geng-Hao Liu, Chang Gung Memorial Hospital

Translational Research on Acupuncture Modulation of Sleep Fragmentation and Glymphatic Function in Aging: A Single-Arm Pilot Study

This single-group pilot study will enroll 20 adults aged 60 years or older with persistent poor sleep. All participants will receive a standardized 6-week acupuncture program. The study will assess feasibility and preliminary changes in actigraphy-derived sleep fragmentation, self-reported sleep, brain DTI-ALPS imaging, internal jugular venous ultrasonography, and CERAD-NB word-list memory performance.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

After written informed consent, participants will complete cognitive and mood screening. Baseline assessments include PSQI, ISI, ESS, CERAD-NB word-list memory testing, one night of home polysomnography, 7 days of actigraphy, brain MRI for the DTI-ALPS index, and internal jugular venous ultrasonography. Participants will then receive acupuncture twice weekly for 6 weeks, for 12 sessions, with each session lasting approximately 20 to 30 minutes. ISI will also be assessed at Weeks 2 and 4. At Week 6, baseline assessments will be repeated except for home polysomnography. PSQI, ISI, and ESS will be collected again approximately 3 months after treatment as an optional follow-up. Missing data from this optional follow-up alone will not exclude a participant from the per-protocol population. Exploratory analyses will examine whether actigraphy-derived physical activity and light exposure are associated with, or modify, changes in the registered sleep, imaging, and cognitive outcomes.

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Taïwan
    • Taoyuan
      • Taoyuan, Taoyuan, Taïwan, 333
        • Linkou Chang Gung Memorial Hospital
        • Contact:
      • Taoyuan, Taoyuan, Taïwan, 333
        • Taoyuan Chang Gung Memorial Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 60 years or older.
  2. Subjective poor sleep for at least 3 months.
  3. Pittsburgh Sleep Quality Index (PSQI) total score greater than 5.
  4. Willing and able to complete study assessments and the 6-week intervention.
  5. Mini-Mental State Examination (MMSE) score of 24 or higher.
  6. Provides written informed consent.

Exclusion Criteria:

  1. Diagnosed dementia, Parkinson disease, or another progressive neurodegenerative disorder.
  2. Stroke or severe head injury within the prior year.
  3. Unstable major psychiatric illness.
  4. AD8 score of 2 or higher or Geriatric Depression Scale (GDS) score of 5 or higher.
  5. Severe sensory or comprehension problems that prevent study participation.
  6. Night-shift work or frequent recent transmeridian travel.
  7. Current CPAP or BiPAP use, or severe obstructive sleep apnea requiring immediate treatment, such as an apnea-hypopnea index greater than 30 with oxygen desaturation.
  8. Use of 3 or more hypnotic medications with inability to maintain a stable dose.
  9. Contraindication to magnetic resonance imaging.
  10. Major neck surgery, neck radiation, or vascular anomaly that interferes with jugular ultrasonography.
  11. Severe unstable systemic disease.
  12. Severe coagulopathy or anticoagulation that makes acupuncture unsuitable.
  13. Infection or wound at an acupuncture site.
  14. Severe gait instability or inability to attend scheduled visits.
  15. Any other condition that the investigator considers unsuitable for participation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Acupuncture

Participants receive a 6-week standardized acupuncture program.
Procédure: Acupuncture

Participants will receive acupuncture at Baihui (GV20), Anmian (EX-HN22), Zusanli (ST36), and Taixi (KI3) twice weekly for 6 weeks, for a total of 12 sessions. Needles will be retained for approximately 20 to 30 minutes per session. No comparator arm is used in this pilot.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in 7-day mean wake after sleep onset from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Wake after sleep onset (WASO) is the total minutes scored awake between sleep onset and final awakening for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: minutes.
Baseline and Week 6

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in 7-day mean sleep efficiency from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Sleep efficiency is the percentage of time in bed scored as sleep for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: percentage points.
Baseline and Week 6
Change in Pittsburgh Sleep Quality Index total score over time
Délai: Baseline, Week 6, and approximately 3 months after treatment

The Pittsburgh Sleep Quality Index total score ranges from 0 to 21; higher scores indicate poorer sleep quality. Change at Week 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Week 6, and approximately 3 months after treatment
Change in 7-day mean number of awakenings from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. Actiware-derived awakenings are counted for each valid night. Sleep is measured with Actiwatch 2 (Philips Respironics) worn on the nondominant wrist, recorded in 60-second epochs, and scored with Philips Actiware version 6.0.9 using sleep diaries. Each timepoint is the mean across all valid nights in the 7-day assessment window. A timepoint is valid if it includes at least 5 valid nights, including at least 1 weekend night; otherwise it is treated as missing. Unit: awakenings per night.
Baseline and Week 6
Change in 7-day mean sleep fragmentation index from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 mean minus the baseline mean. For each valid night, the Actiware 6.0.9 sleep fragmentation index is the sum of (1) the percentage of epochs classified as mobile during the sleep interval and (2) the percentage of all immobile bouts lasting no more than 1 minute. Higher values indicate greater sleep fragmentation. Actiwatch 2 is worn on the nondominant wrist and recorded in 60-second epochs. Each timepoint is the mean across valid nights in the 7-day window. A timepoint requires at least 5 valid nights, including at least 1 weekend night; otherwise it is missing. Unit: percentage points.
Baseline and Week 6
Change in Insomnia Severity Index total score over time
Délai: Baseline, Weeks 2, 4, and 6, and approximately 3 months after treatment

The Insomnia Severity Index total score ranges from 0 to 28; higher scores indicate greater insomnia severity. Change at Weeks 2, 4, and 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Weeks 2, 4, and 6, and approximately 3 months after treatment
Change in Epworth Sleepiness Scale total score over time
Délai: Baseline, Week 6, and approximately 3 months after treatment

The Epworth Sleepiness Scale total score ranges from 0 to 24; higher scores indicate greater daytime sleepiness. Change at Week 6 and at the optional approximately 3-month post-treatment follow-up equals the respective follow-up score minus baseline.
Baseline, Week 6, and approximately 3 months after treatment
Change in diffusion tensor imaging along the perivascular space index from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 value minus the baseline value for the diffusion tensor imaging along the perivascular space (DTI-ALPS) index. Unit: unitless (dimensionless index).
Baseline and Week 6
Change in side-specific internal jugular vein time-averaged mean blood-flow velocity from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 value minus baseline for time-averaged mean velocity measured by pulsed-wave Doppler ultrasonography with the participant supine and the head in a neutral position. The left and right internal jugular veins are measured and analyzed separately; values are not combined by a simple bilateral average. Repeated measurements for each side are averaged. Unit: centimeters per second (cm/s).
Baseline and Week 6
Change in side-specific internal jugular vein cross-sectional area from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 value minus baseline for cross-sectional area measured by transverse B-mode ultrasonography with the participant supine and the head in a neutral position. The left and right internal jugular veins are measured and analyzed separately; values are not combined by a simple bilateral average. Repeated measurements for each side are averaged. Minimal transducer pressure is used to avoid vein compression. Unit: square centimeters (cm²).
Baseline and Week 6

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in CERAD-NB word-list memory composite score from baseline to Week 6
Délai: Baseline and Week 6

Change equals the Week 6 score minus baseline. The composite is the sum of word-list learning across 3 trials (0-30), delayed recall (0-10), and recognition discriminability (0-10), for a total range of 0-50; higher scores indicate better memory performance. Recognition discriminability is calculated as correct "Yes" responses plus correct "No" responses minus 10; values below 0 are scored as 0. Remote memory is not included in this composite.
Baseline and Week 6
Proportion of participants completing at least 10 of 12 acupuncture sessions
Délai: Through Week 6

Number of enrolled participants who complete at least 10 of the 12 planned acupuncture sessions divided by the total number enrolled, multiplied by 100. This threshold corresponds to at least 80% treatment adherence. Unit: percentage of participants.
Through Week 6
Proportion of participants completing the Week 6 primary outcome assessment
Délai: Week 6

Number of enrolled participants who complete the Week 6 assessment of the primary outcome, 7-day mean wake after sleep onset, divided by the total number enrolled, multiplied by 100. Unit: percentage of participants.
Week 6
Proportion of participants with valid actigraphy data at both baseline and Week 6
Délai: Baseline and Week 6

Number of enrolled participants with valid actigraphy timepoints at both baseline and Week 6 divided by the total number enrolled, multiplied by 100. Each timepoint requires at least 5 valid nights, including at least 1 weekend night. Unit: percentage of participants.
Baseline and Week 6

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Chang Gung Memorial Hospital

Collaborateurs

National Science and Technology Council, Taiwan

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

31 juillet 2027

Achèvement de l'étude (Estimé)

31 octobre 2027

Dates d'inscription aux études

Première soumission

20 septembre 2026

Première soumission répondant aux critères de contrôle qualité

20 septembre 2026

Première publication (Réel)

25 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 202502000A3-PILOT
  • NSTC 115-2320-B-182-022-MY3 (Autre subvention/numéro de financement: National Science and Technology Council, Taiwan)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner